First, the broad inclusion criteria, which considered patients with varying durations of diabetes, both insulin- and noninsulin-treated, and with a clinically relevant and realistic HbA1c spectrum, provided a not overselected patient population. This evidence concerns the gene INS and diabetes mellitus.